SGF29-IN-1 (Compound Cpd_DC60) serves as a selective inhibitor targeting the Tudor domain of the Spt-Ada-Gcn5 acetyltransferase (SAGA)-associated factor 29 (SGF29). It has demonstrated effectiveness in treating leukemia [1].

SGF29-IN-1 (20 μM) inhibits the Tudor domain of SGF29, disrupting SGF29-dependent acetylation of H3K9 in leukemia cell lines MOLM13 and MV4-11 [1]. Western Blot Analysis [1] Cell Lines: MOLM13 and MV4-11, Concentration: 20 μM, Incubation Time: 48 hours, Result: Inhibited acetylation of H3K9 and reduced levels of RPL8 and RPS2.

SGF29-IN-1, administered at 5 mg/kg via intraperitoneal injection every other day for 35 days, effectively inhibits leukemia progression in a mouse model (MLL-AF9 xenograft CD45 mice) with no significant toxicity to CD45 mice [1]. This treatment leads to a reduced percentage of 45.2 cells in the peripheral blood and spleen and improves the survival rate of the rats.